drugset
drugset / Trial / NCT04003246

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

NCT04003246 ↗

Phase 2 Completed 10 enrolled University of Texas Southwestern Medical Center AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

Single arm, Phase II trial of concurrent Durvalumab (MEDI 4736) and radiotherapy followed by consolidative Durvalumb (MEDI 4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)

Timeline

Start
2020-04-03
Primary completion
2022-06-15
Completion
2024-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 1500 mg Intravenous

Indications

non-small cell lung carcinoma